Hamburg, 12 Juli 2018 – The international law firm BEITEN BURKHARDT has advised the Tübingen-based healthcare investor SHS Gesellschaft für Beteiligungsmanagement on the sale of all its shares in the specialty pharmaceuticals company AMW GmbH, including its subsidiary Endomedica GmbH, to Hybio Pharmaceutical and YF Capital. The transaction shall be executed in several steps. The parties have agreed not to disclose the transaction volume.

Besides SHS Gesellschaft für Beteiligungsmanagement, the existing shareholders have been the founders of the company, funds managed by Bayern Kapital, KfW, IBG Risikokapitalfonds II, BayBG Bayerische Beteiligungsgesellschaft and UVC Partners. The investors had assisted AMW for a couple of years and in 2016 provided EUR 6 million in a fifth financing round. The strategic sale of the participation is targeted at promoting the international growth of the specialty pharmaceuticals company.

AMW GmbH is a pharmaceutical company that has specialised in novel drug release systems. These products allow for a drug delivery through transdermal application such as patches or subcutaneous implants. The company was established in 2008 and is dedicated to the development of therapeutic solutions in the fields of oncology, neurology, dermatology and pain therapy. AMW is domiciled in the Upper Bavarian Warngau whereas Endomedica, the subsidiary sold along, is based in Halle (Saale).

The Chinese purchaser consortium consisting of Hybio Pharmaceutical and YF Capital, shall successively acquire 100 percent of the shares in AMW GmbH. Hybio Pharmaceutical is a leading biopharmaceutical company, concentrating on research, development, manufacture and distribution of peptides and peptide-based drugs. YF Capital is a private equity company, founded by successful businessmen and influential industry giants such as, among others, the former Executive Chairman of Alibaba Group (Jack MA (Yun)). The acquisition of AMW is part of the international growth strategy pursued which is focussing particularly on the expansion of the product portfolio and the R&D pipeline.

This international M&A transaction shows once again the close ties BEITEN BURKHARDT maintains especially with Chinese investors, and the successful cooperation of experts across offices.

Advisor to Vendor Consortium
BEITEN BURKHARDT: Partner Oliver Köster, LL.M. (Lead Partner, Corporate/M&A, Hamburg) and Associate Tassilo Klesen (Corporate/M&A, Berlin).
LUTZ | ABEL Rechtsanwalts GmbH: Dr Bernhard Noreisch (Munich).

Advisor to Founders
Weitnauer Rechtsanwälte: Dr Wolfgang Weitnauer.

Contact
Oliver Köster
Phone: +49 40 68 87 45 – 118
E-mail: Oliver.Koester@bblaw.com

Public Relations
Frauke Reuther
Phone: +49 69 75 60 95 – 570
E-mail: Frauke.Reuther@bblaw.com